两家独立企业由此诞生
生命科学与诊断 & 分析和企业服务
专注于生命科学和诊断业务的高增长型公司,推动科学家和医疗卫生专业人士的研究、发现和检测,助力打造更健康的世界
我们专注于提供全方位的分析和企业服务解决方案,包括领先的OneSource实验室服务,加速您的科学研究进程
A major stage in biotherapeutic development is to understand the immunogenicity, pharmacokinetics (PK), and pharmacodynamics (PD) of the drug candidate to evaluate both an immune system response as well as in vivo metabolism of the biologic drug, respectively. Interpreting, assessing, and predicting immunogenicity is therefore critical in the development of a biotherapeutic.
Predicting and assessing immunogenicity early in drug discovery ensure the likelihood of success as the biologic drug candidate progresses through the discovery and development pipeline. Pharma and Biopharma companies may have their own proprietary methods for immunogenicity and PK/PD assessment as part of their developability scoring.
PerkinElmer offers a complete solution of tools to help developability scoring, which represents our informatics solution to help predict known sequence activity relationships, to in vivo biodistribution studies and through a variety of immunoassay platforms.